Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

ERIVEDGE: metastatic Basal Cell Carcinoma after prior therapy

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

1 INDICATIONS AND USAGE ERIVEDGE is indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery and who are not candidates for radiation.

Broader topic: Basal Cell Carcinoma

Source population
Not part of this definition
Disease extent
metastatic
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
    prior therapy
    1. class
      following surgery or who are not candidates for surgery and who are not candidates for radi
      status
      required
    derivation status
    source-attested
    derivation note
    Scoped from the FDA approved indication for ERIVEDGE (product label). Only dimensions stated in that wording are part of this definition.
    source wording
    1 INDICATIONS AND USAGE ERIVEDGE is indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery and who are not candidates for radiation.

    Study evidence for this setting

    4 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

    NCT00492089 · Registry condition search · Scope: unclear

    Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer

    1 outcome links · 2 safety-group records · 0 quality-of-life measures

    →

    NCT01327053 · Source cited / selected · Scope: unclear

    A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

    6 outcome links · 2 safety-group records · 0 quality-of-life measures

    →

    NCT01806675 · Registry condition search · Scope: unclear

    18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy

    5 outcome links · 3 safety-group records · 1 quality-of-life measures

    →

    NCT02123511 · Registry condition search · Scope: unclear

    Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy

    6 outcome links · 2 safety-group records · 3 quality-of-life measures

    →
    Source relationships and population-mapping limitations
    bindings
      mappings

        Download this complete draft source relationship record →

        Preserved source evidence · Not medical advice